Because a plausible mechanism of risperidone-induced edema remains unknown, further investigation is warranted to elucidate the risk factors and potential mechanisms of the edema.
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Risperidone, a benzisoxazole derivate, is a widely prescribed antipsychotic agent that binds with high affinity to dopamine D2, serotonin type 2 (5-HT2) and α1-adrenergic receptors, and causes antagonism at these receptor sites.
📊
Key Findings & Data:Although risperidone has several side effects such as weight gain and sedation, edema is a very rarely observed side effect in children and adolescents.
💡
Conclusion & Impact:Because a plausible mechanism of risperidone-induced edema remains unknown, further investigation is warranted to elucidate the risk factors and potential mechanisms of the edema.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Özet
Risperidone, a benzisoxazole derivate, is a widely prescribed antipsychotic agent that binds with high affinity to dopamine D2, serotonin type 2 (5-HT2) and α1-adrenergic receptors, and causes antagonism at these receptor sites. Although risperidone has several side effects such as weight gain and sedation, edema is a very rarely observed side effect in children and adolescents. Here, we report a case of facial edema in a child with conduct disorder (CD) who was receiving low-dose of oral solution risperidone. Three days after risperidone discontinuation, the facial edema resolved entirely. Because a plausible mechanism of risperidone-induced edema remains unknown, further investigation is warranted to elucidate the risk factors and potential mechanisms of the edema.
🔖
Cite This Article
AYAYDIN, H., ULGAR, Ş. B. (2018). Low-Dose Risperidone-Induced Facial Edema in a Child with Conduct Disorder. Psychiatry and behavioral sciences (Online), Cilt: 8 - Sayı: 1, 35–37. https://ajindex.com/articles/302840
Tamam L, Ozpoyraz N, Unal M. Oedema associated with risperidone: a case report and literature review. Clin Drug Investig 2002;22(6):411–14. [CrossRef] Stigler KA, Potenza MN, McDougle CJ. Tolerability profile of atypical antipsychotics in children and adolescents. Paediatr Drugs 2001;3(12):927-42. [CrossRef] Ercan ES, Amado S, Somer O, Çıkoğlu S. Development of a test battery for the assessment of attention deficit hyperactivity disorder. Turkish Journal of Child And Adolescent Mental Health 2001;8:132-45. (Turkish) Kose S, Akin E, Cetin M. Adverse drug reactions and causality: the Turkish version of Naranjo Adverse Drug Reactions Probability Scale. Psychiatry and Clinical Psychopharmacology 2017;27(2):205-6. [CrossRef] Feroz-Nainar C, Selvaraj P, Roy M. Risperidone induced oedema in a child with learning disability and autism. Autism 2006;10(3):308-10. [CrossRef] Soumya RN, Frover S, Dutt A, Gaur N. Angioneurotic edema with risperidone: a case report and review of literature. Gen Hosp Psychiatry 2010;32:646.e1- 646.e3. [CrossRef] Akdag ST, Fettahoglu EC, Ozatalay E. Pedal edema induced by low-dose risperidone monotheraphy in a child. J Child Adolesc Psychopharmacol 2009;19(4):481-2. [CrossRef] Franco K, Tamburrino M, Campbell N, Pentz J, Evans C. Dopaminergic activity and idiopathic edema. Hosp Community Psychiatry 1991;42(3):309-10. [CrossRef] Terao T, Kojima H, Eto A. Risperidone and allergic reactions. J Clin Psychiatry 1998;59(2):82-3. [CrossRef] Knox ED, Stimmel GL. Clinical review of a long-acting, injectable formulation of risperidone. Clin Ther 2004;26(12):1994-2002. [CrossRef] Yaluğ I, Ozten E, Evren Tufan A, Alemdar M, Cerit C. Bilateral pedal edema associated with olanzapine use in manic episode of bipolar disorder: report of two cases. Prog Neuropsychopharmacol Biol Psychiatry 2007;31(7):1541-2. [CrossRef] Yang HN, Cheng YM. Peripheral edema associated with risperidone oral solution: a case report and a review of the literature. J Clin Psychopharmacol 2012;32(1):128-30. [CrossRef]